Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.

Apellis Pharmaceuticals APLS announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the label expansion of Empaveli (pegcetacoplan) for two rare and severe kidney ...

In trading on Monday, shares of Apellis Pharmaceuticals Inc (Symbol: APLS) entered into oversold territory, hitting an RSI reading of 26.7, after changing hands as low as $21.89 per share.

Investors in Apellis Pharmaceuticals Inc (Symbol: APLS) saw new options begin trading this week, for the May 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...

The Fairhope Public Library Board will decide whether to review books deemed "sexually explicit" by the Alabama Public ...

Scotiabank analyst Greg Harrison maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at ...

FAIRHOPE, Ala. (SBG) — Alabama Public Library Service Chairman John Wahl has released a message to Fairhope residents weeks ...

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.

Analysts at William Blair lifted their Q2 2026 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, April 1st. William Blair analyst L.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...